Published: 31. May, 2021
Clinical trial 0204 in 12 healthy volunteers investigating the absolute bioavailability of CT001, reports…
Clinical trial 0204 in 12 healthy volunteers investigating the absolute bioavailability of CT001, reports last subject dosed ahead of timelines. Primary aim of the trial is to demonstrate drug-exposure following nasal administration of CT001 relative to the IV injection of the approved analgesic drugs
25. October, 2023
The European Paediatric Committee (PDCO) has agreed to a 50% reduction in the number...
21. September, 2023
Last participant has been randomised in clinical trial 0205 investigating efficacy and safety of...
12. September, 2023
On 12 September – Cessatech A/S (“Cessatech” or “the Company”) announces that EMA’s Paediatric...
Subscribe and get notified on Cessatech's latest news.
An acceptance email will be sent to you, please check your spam.